Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.33 |
| ▸ | PDE5A | O76074 | 6/20 | 0.33 |
| ▸ | PDE4A | P27815 | 6/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.33 |
| ▸ | GNRHR | P30968 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769379 | 0.82 | ALDH1A1 (0.42) | PDE4DPDE5APDE4APDE4BPDE4C | |
| SCHEMBL4767817 | 0.81 | PARG (0.38) | PDE4DPDE5APDE4APDE4BPDE4C | |
| SCHEMBL4771274 | 0.78 | PDE5A (0.46) | PDE4DPDE5APDE4APDE4BPDE4C | |
| SCHEMBL4762679 | 0.78 | PDE5A (0.33) | PDE5AGNRHRPDE1APDE1BPDE1C | |
| SCHEMBL4767318 | 0.77 | AR (0.34) | PDE4DPDE5APDE4APDE4BPDE4C | |
| SCHEMBL4767961 | 0.76 | PDE4D (0.38) | PDE4DPDE5APDE4APDE4BPDE4C | |
| SCHEMBL4767673 | 0.75 | PDE5A (0.53) | PDE4DPDE5APDE4APDE4BPDE4C | |
| SCHEMBL4771049 | 0.73 | MAPT (0.37) | — | |
| SCHEMBL4765718 | 0.72 | PDE4D (0.46) | PDE4DPDE5APDE4APDE4BPDE4C | |
| SCHEMBL4771453 | 0.72 | ADORA3 (0.44) | PDE4DPDE5APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | PDE4D 341/4885PDE5A 736/4885PDE4A 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.